Machine Recycling Discussion and Moderated Newsgroup > Separate Parts
> Knobs and Handles
> South
> New
> Vasomedical model TS4 eecp therapy system
Vasomedical model TS4 eecp therapy system
VASOMEDICAL MODEL TS4 EECP THERAPY SYSTEM
Counterpulsation is a treatment method to increase blood flow in the body and reduce workload of the heart. External counter pulsation (ECP) is a term used to describe systems using a single hydraulic chamber wrapped around the lower extremities. Pressure is applied to the chamber during cardiac diastolic relaxation phase and removed during ejection systolic phase. The devices were inefficient and difficult to use. During the past 15 years, technological and clinical advancement led to the development of EECP - Enhanced External Counter pulsation, the therapeutic systems exclusively designed and manufactured by Vasomedical with sequential pneumatic compression to increase retrograde diastolic flow, venous return and systolic unloading, greatly improve the ease of use, patient safety and clinical effectiveness.
Since the development of EECP , an abundance of research has reviewed the mechanisms of action associated with the overwhelming positive benefits in patients who undergo a course of EECP therapy. Only EECP has been proven clinically to produce the acute hemodynamic effects associated with increased diastolic augmentation, systolic unloading, and increased cardiac output, with a decrease in myocardial oxygen requirements. More recently, concrete evidence supports many of the hypotheses as to how exposure to EECP treatment and its positive acute hemodynamic benefits can also recruit collateral blood vessels to ischemic regions, improve neurohormonal factors, improve endothelial function, reduce proinflammatory cytokines and adhesion molecules, and reduce arterial stiffness. All of these combined factors assist in the improvement of blood flow to ischemic regions and explain the life-changing clinical benefits observed in the majority of patients who undergo a course of EECP therapy. Furthermore, it has been observed repeatedly that cardiac patients who undergo EECP treatment have seen improvement in circulatory processes in systems other than cardiac (i.e. diabetic neuropathy, PVD, erectile dysfunction, etc ) and these findings will hopefully lead to more research to expand the indications for use of external counterpulsation not just for cardiac patients but for many patients who suffer from diseases of the circulatory system in the future.
EECP (Enhanced External Counterpulsation) systems are FDA cleared non-invasive medical devices used as an adjunctive treatment for patients who suffer from coronary artery disease or ischemic heart failure. CMS (Centers for Medicare and Medicaid Services) reimbursement coverage has been provided for the use of ECP since 1999 for patients who have been diagnosed with disabling angina (Class III or Class IV, Canadian Cardiovascular Society Classification or equivalent classification) and whom are not readily amendable for interventional procedures. EECP therapy is a low-risk, cost-effective option for patients who suffer from coronary artery disease and its associated symptoms.
